medigraphic.com
ISSN 0188-9796 (Impreso)

2002, Número 4

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2002; 10 (4)


Niveles de fibrinógeno en plasma en pacientes con diabetes mellitus tipo 2, con infecciones y otras enfermedades intercurrentes

Garay-Sevilla ME, Malacara A, Malacara JM, González F

Idioma: Español
Referencias bibliográficas: 30
Paginas: 195-200
Archivo PDF: 99.87 Kb.


RESUMEN

Objetivo: El objetivo del estudio fue investigar los niveles de fibrinógeno en plasma de pacientes con diabetes mellitus tipo 2 (DM2) con infecciones y otras enfermedades intercurrentes. Material y métodos: En un estudio clínico en sección transversal examinamos los niveles de fibrinógeno en plasma en 100 pacientes (58 mujeres y 42 hombres) con DM2, clasificados en cuatro grupos: 1) sin complicaciones, 2) con complicaciones de la diabetes, 3) con enfermedades intercurrentes no infecciosas, y 4) con infecciones agudas o crónicas. Resultados: Se encontraron cifras más altas de fibrinógeno en los grupos 3 (483 ± DE 145.4) y 4 (496 ± 192.3), de albuminuria en los grupos 2 y 3 (F = 8.1 p ‹ 0.001) y de creatinina en el grupo 2 (F = 10.8 p ‹ 0.001). Se encontraron diferencias entre los grupos para los años desde el diagnóstico (p= 0.017), índice de masa corporal en mujeres (p= 0.034) y presión arterial sistólica (p= 0.007). En el análisis de regresión múltiple, el fibrinógeno se asoció con albúmina (p‹ 0.001), y el colesterol-HDL (negativamente) (p= 0.004). Conclusiones: Concluimos que en la DM2, las enfermedades intercurrentes como infecciones u otras afecciones médicas o quirúrgicas, se asocian con incrementos claros de fibrinógeno en plasma. Este factor debe ser evaluado en dichos pacientes porque significa un riesgo adicional para la progresión de las complicaciones vasculares.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Roeters van Lennep JE, Westrerveld HT, Erkelens DW, vander Wall EE. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002; 15; 53(3): 538-49.

  2. Stec JJ, Silbershatz H, Tofler GH, Matheney TS, Sutherland P, Lipinska I, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000; 102(14): 1634-8.

  3. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D’Errico N, Maechia G, et al. Hyperfibrinogenemia and metabolic syndrome in type 2 diabetes: a population-based study. Diabetes Metab Res Rev 2001; 17(2): 124-30.

  4. Ganda OP, Arkin CF. Hyperfibrinogenemia. An important risk factor vascular complications in diabetes. Diabetes Care 1992; 15: 1245-1250.

  5. Fowkes FGR, Donnan PT, Prescott RJ, Connor JM. Fibrinogen genotype and risk of peripheral atherosclerosis. The Lancet 1992; 339: 693-695.

  6. Jen CJ, Lin JS. Direct observation of platelet adhesion to fibrinogen and fibrin-coated surfaces. Am J Physiol 1991; 261: H1457-H1463.

  7. Yamada T, Sato A, Nishimori T, Mitsuhashi T, Tarao A, Sagai H, et al. Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes. Diabetes Res Clin Pract 2000; 49(1): 23-31.

  8. Ernst E. Fibrinogen as a cardiovascular risk factor-interrelationship with infections and inflammation. Eur Heart J 1993; 14 suppl: 82-87.

  9. Bucala R, Cerami A, Vlassara H. Advanced glycosylation end products in diabetes complications. Diabetes Reviews 1995; 3: 258-268.

  10. Garay-Sevilla ME, Nava LE, Malacara JM, Wröbel K, Wróbel K, Pérez U. Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus (DM). Diabetes Metab Res Rev 2000; 16: 106-113.

  11. Ernst E. Plasma fibrinogen-and independent cardiovascular risk factor. J Int Med 1990; 227: 365-72.

  12. Mattila KJ. Dental infections as risk factor for acute miyocardial infarction. Eur Heart J 1993; 14 suppl 1: 51-3.

  13. Patel P, Carrington D, Strachan DP, Leatham E, Goggin P, Northfield TC, Mendall MA. Fibrinogen: a link between chronic infection and coronary heart disease. The Lancet 1994; 343: 1634-5.

  14. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol 2001; 52 suppl: 13-31.

  15. Temelkova-Kurktschiev T, Siergert G, Bergmann S, Henkel E, Koehler C, Jaros W, Hanefeld M. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in hight risk population for diabetes. Metabolism 2002; 51: 743-49.

  16. Kriska AM, Kmowler WC, La Porte RE, et al. Development of questionaire to examine relationship of physical activity and diabetes in pima indians. Diabetes Care 1990; 13: 401-411.

  17. Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects. The insulin resistance atherosclerosis study. Kidney Int 2000; 58(4): 1703-10.

  18. The DCCT group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.

  19. Asakawa H, Tokunaga K, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications 2000; 14(3): 121-6.

  20. Vanninen E, Laitinen J, Uusituoa M. Physical activity and fibrinogen concentration in newly diagnosed NIDDM. Diabetes Care 1994; 9: 1031-1038.

  21. Ceriello A, Taboga C, Giacomello R, et al. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 1994; 43: 430-32.

  22. Jain A, Gupta HL, Narayan S. Hyperfibrinogenemia in patients of diabetes mellitus in relation to glycemic control and urinary albumin excretion rate. J Assoc Physicians India 2001; 49: 227-30.

  23. Fuller JH, Keen H, Jarret RJ, et al. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964-66.

  24. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appeby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000; 321: 199-203.

  25. Rifai N, Joubran R, Yu H, Asmi M, Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 1999; 45: 1967-1973.

  26. Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Luis AJ. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997; 96: 2914-2919.

  27. Sterm MP. Diabetes and cardiovascular disease: The common soil hypothesis. Diabetes 1995; 44: 369-374.

  28. Festas A, D’Agostino Jr R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 2002; 51: 1131-1137.

  29. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W, Hanefeld M. Subclinical inflammation in strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51: 743-749.

  30. Gluckman PD. Editorial: Nutrition, glucocorticoids, bith size, and adult disease. Endocrinology 2001; 142: 1689-1691.




2020     |     www.medigraphic.com